©2024 Stanford Medicine
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
Not Recruiting
Trial ID: NCT01874054
Purpose
The purpose of this study is to assess safety and efficacy of brentuximab vedotin in
combination with bendamustine in patients with relapsed or refractory Hodgkin lymphoma. It is
an open-label, 2-stage study designed to determine the recommended dose level of bendamustine
in combination with brentuximab vedotin. The study will assess the safety profile of the
combination treatment and determine what proportion of patients achieve a complete remission.
Official Title
A Phase 1/2 Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Stanford Investigator(s)
Ranjana Advani
Saul A. Rosenberg, MD, Professor of Lymphoma
Hans-Christoph Becker, MD, FSABI, FSCCT
Clinical Professor, Radiology
Eligibility
Inclusion Criteria:
- Histopathological diagnosis of classical Hodgkin lymphoma
- Failed standard front-line therapy
- Measurable disease of at least 1.5 cm as documented by radiographic technique
- Eastern Cooperative Oncology Group performance status less than or equal to 2
Exclusion Criteria:
- Received prior salvage therapy, including radiotherapy
- Chemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not
completed 4 weeks prior to first dose of study drug
- Concurrent use of other investigational agents
Intervention(s):
drug: brentuximab vedotin
drug: bendamustine
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061